Christopher S Hourigan

Targets

• FLT3 1
• NPM1 1

Filled chips are declared by the researcher; the others come from publications (number of works).

Now

Trials, publications and grants since Nov 2024.

• Publication

  Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

  The New England journal of medicine, Sept 2026

• Publication

  ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

  Blood, Aug 2026

• Publication

  2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

  Blood, Mar 2026

• Publication

  CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

  Blood, Mar 2026

• Preprint

  Genomics of Acute Myeloid Leukemia at Diagnosis and Remission.

  medRxiv : the preprint server for health sciences, Dec 2025

• Publication

  Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia.

  Bone marrow transplantation, Nov 2025

Affiliations

• Centro de Investigación del Cáncer

Co-authors

• MSMarion SubkleweHow are we linked?

Who links you

Enter another researcher's profile link or ID to see who has published with both of you.